ArticleThe American journal of case reports2026
Systemic Lupus Erythematosus With IgA Nephropathy: Challenges in Diagnosis and Management.
Article in The American journal of case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Systemic lupus erythematosus (SLE) commonly involves the kidneys, most often as lupus nephritis (LN), which affects up to 60% of patients who have SLE, and is a major cause of morbidity. IgA nephropathy (IgAN), the most common primary glomerulonephritis, follows a benign course but rarely coexists with SLE. This overlap creates a significant diagnostic dilemma because both conditions present with proteinuria, hematuria, and impaired kidney function. Whether this demonstrates a causal link or a simple coincidence remains debated. CASE REPORT We present the case of a young woman with diagnosed SLE, previously complicated by seizures, who presented with nephrotic-range proteinuria, edema, and hematuria, mimicking a LN flare. She met the EULAR/ACR criteria for SLE exclusive of renal involvement. However, renal biopsy revealed dominant mesangial IgA deposition without IgG or C1q, with an Oxford MEST-C score of M1E0S1T0C0, confirming IgAN. Early immunosuppression was administered, owing to the severity of the presentation. This resulted in marked improvement, with proteinuria decreasing significantly and stabilization of renal function on follow-up. CONCLUSIONS This case illustrates that severe IgAN can occur in patients with SLE and be clinically indistinguishable from an LN flare. Careful histopathological assessment, particularly immunofluorescence, is important to differentiate IgAN from classic LN, as management may differ. The aggressive presentation and favorable response to immunosuppression suggest that active SLE can exacerbate underlying IgAN. This co-occurrence raises questions about whether IgA-dominant nephritis in SLE is an incidental finding or is a linked pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.